ClinicalTrials.gg
RecruitingNCT06221852Updated Aug 17, 2026

Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder

An interventional study of Ketogenic diet and Dietary Guidelines for Americans in Bipolar I Disorder, Psychosis and Schizoaffective Disorder, sponsored by Mclean Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Mclean Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Psychotic Disorders by Mclean Hospital — 6 open to participants now, 6 under way, none of them phase 3. Psychotic Disorders · Mclean Hospital.

Planned enrollment
8th of 17
50 · median 50
Started
2024
with 3 others
No phase
11 of 18
6 open now
Registered
16th of 18
by date

Among the 18 studies in Psychotic Disorders by Mclean Hospital, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 with no phase, and was the 16th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

6 of the 18 studies in Psychotic Disorders by Mclean Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Psychotic Disorders by Mclean Hospital, or all of them as a file.
02

Study summary

This is a randomized, controlled clinical trial to assess the effects of the ketogenic diet in combination with treatment as usual on brain energy metabolism and psychiatric symptoms in individuals with first episode bipolar disorder and schizoaffective disorder.

Read the detailed description

Several lines of evidence show energy metabolism and redox dysregulation in bipolar disorder and psychotic disorders. Ketogenic interventions targeting energy metabolism are promising therapeutic approaches to improve mood and psychosis in bipolar disorder and other psychotic disorders. Early intervention is also critical to helping people achieve their goals for recovery after a first episode. Investigators aim to use multimodal imaging and metabolic measures to study the effects of a ketogenic diet intervention on energy metabolism and psychiatric symptoms in individuals with first episode bipolar disorder and schizoaffective disorder. This 12-week randomized controlled trial will assess the benefits of a ketogenic diet in combination with treatment as usual compared to a standard diet. Investigators will measure the effects of nutritional ketosis on brain redox and energy metabolism and other neurometabolic markers using magnetic resonance spectroscopy. Furthermore, investigators will measure the effects of the ketogenic diet on mood and psychotic symptoms and metabolic measures such as insulin resistance.

03

Conditions studied

  • Bipolar I Disorder
  • Psychosis
  • Schizoaffective Disorder

Keywords

  • First episode psychosis
  • Ketogenic Diet
  • Keto
  • Brain energy metabolism
  • Insulin resistance
  • Schizoaffective Disorder
  • Bipolar Disorder
  • Magnetic resonance spectroscopy (MRS)
  • Redox
  • Creatine kinase
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between the ages of 18 and 45.
  • Ability to adhere to study diets.
  • -5 (DSM-5) diagnosis of bipolar I disorder or schizoaffective disorder with onset of illness in the last 7 years.
  • Must have a stable psychiatric disorder with no change in psychiatric medications within the past 2 weeks of screening
  • Must not be expected to require addition of any new psychiatric medications during the 12-week duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Unable to sign
  • to magnetic resonance (MR) scan (including claustrophobia)
  • Unstable medical illness (including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease)
  • Current substance use disorder
  • Currently pregnant, nursing, or of and not using a medically accepted means of
  • Have a body weight of over 350 lbs or a (BMI) \<20
  • Score above 15 on the Young Mania Rating Scale (YMRS)
  • History of significant head injury
  • Current cancer diagnosis
  • Current diagnosis of type 1 or type 2 Diabetes Mellitus
  • History of gastric bypass surgery or any weight loss surgery
  • Concomitant treatment with Propofol
  • Familial hypercholesterolemia
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Ketogenic diet arm

    Eligible participants assigned to the ketogenic diet arm will be asked to follow the ketogenic diet (KD) for 12 weeks in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive weekly and as needed diet counseling from a registered dietician. Participants will be asked to monitor and report their blood ketone levels each day via a finger-prick device provided by the study team. Participants have the ability to opt into an optional open label phase where they can continue on the ketogenic diet with the daily finger pricks for another 12 weeks after the 12-week main study.

    Other: Ketogenic diet

  • Active comparator
    Dietary Guidelines for Americans arm

    Eligible participants assigned to the Dietary Guidelines for Americans (DGA) arm will adhere to the Dietary Guidelines for Americans in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive weekly and as needed diet counseling from a registered dietician. Participants will be asked to monitor and report their blood ketone levels each day via a finger-prick device provided by the study team. Participants have the ability to opt into an optional open label phase where they can switch to the ketogenic diet with the daily finger pricks for 12 weeks after the 12-week main study.

    Other: Dietary Guidelines for Americans

Interventions

  • OtherKetogenic diet

    The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.

  • OtherDietary Guidelines for Americans

    Dietary Guidelines for Americans diet is a normo-caloric diet consisting of 3 meals a day plus snacks, emphasizing nutrient dense foods to meet food group needs (85% of calories), and limits foods and beverages higher in added sugars and saturated fat (15% of calories).

06

What researchers measure

Primary outcomes

  1. Change in brain redox nicotinamide adenine dinucleotide metabolites ratio (NAD+/NADH)

    Change from baseline to week 12 in NAD+/NADH as measured by in vivo phosphorus magnetic resonance spectroscopy (31P-MRS).

    Time frame: 12 weeks

  2. Change in brain creatine kinase forward reaction rate (kf)

    Change from baseline to week 12 in creatine kinase forward reaction rate (kf) as measured by 31P magnetization transfer (MT) MRS.

    Time frame: 12 weeks

  3. Change in insulin resistance

    Change from baseline to week 12 of insulin resistance measured using the homeostatic model assessment of insulin resistance (HOMA-IR) using fasting blood glucose and insulin levels.

    Time frame: 12 weeks

  4. Change in psychotic symptoms

    Change from baseline to week 12 in Positive and Negative Syndrome Scale (PANSS) total score. Scores range from 30-210; a higher score indicates a higher level of psychotic symptoms.

    Time frame: 12 weeks

  5. Change in depressive symptoms

    Change from baseline to week 12 in Hamilton Rating Scale for Depression (HAM-D) total score. Scores range from 0-52; a higher score indicates a higher level of depression.

    Time frame: 12 weeks

  6. Change in mania symptoms

    Change from baseline to week 12 in Young Mania Rating Scale (YMRS) total score. Scores range from 0-60. A higher score indicates a more severe illness.

    Time frame: 12 weeks

  7. Change in Clinical Global Impression (CGI) Scale

    Change from baseline to week 12 in Clinical Global Impression (CGI) Scale. Scores range from 1-7; a higher score indicates higher severity of illness.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in body weight

    Change from baseline to week 12 in participant body weight in kilograms, as measured using a standing scale.

    Time frame: 12 weeks

  2. Change in glycated hemoglobin (Hemoglobin A1c) level

    Change from baseline to week 12 in fasting Hemoglobin A1c level.

    Time frame: 12 weeks

  3. Change in triglyceride levels

    Change from baseline to week 12 in fasting triglyceride levels.

    Time frame: 12 weeks

  4. Change in low-density lipoprotein (LDL) levels

    Change from baseline to week 12 in fasting LDL levels.

    Time frame: 12 weeks

  5. Change in high-density lipoprotein (HDL) levels

    Change from baseline to week 12 in fasting HDL levels.

    Time frame: 12 weeks

  6. Change in high-sensitivity C-reactive protein (hs-CRP) levels

    Change from baseline to week 12 in fasting hs-CRP levels.

    Time frame: 12 weeks

  7. Change in brain gamma-aminobutyric acid (GABA) concentration

    Change from baseline to week 12 in GABA concentration measured by proton magnetic resonance spectroscopy.

    Time frame: 12 weeks

  8. Change in brain glutamate metabolite concentration

    Change from baseline to week 12 in glutamate metabolite concentration measured by proton magnetic resonance spectroscopy.

    Time frame: 12 weeks

  9. Change in brain glutathione (GSH)

    Change from baseline to week 12 in brain GSH measured by proton magnetic resonance spectroscopy.

    Time frame: 12 weeks

  10. Change in brain Phosphocreatine (PCr)

    Changes from baseline to week 12 in PCr concentration as measured by in vivo 31P-MRS.

    Time frame: 12 weeks

  11. Change in brain pH

    Change from baseline to week 12 in pH as measured by in vivo 31P MRS.

    Time frame: 12 weeks

  12. Change in brain inorganic phosphate concentration

    Change from baseline to week 12 in inorganic phosphate (Pi) concentration as measured by in vivo 31P MRS.

    Time frame: 12 weeks

  13. Change in adverse events

    Change from baseline to week 12 from baseline to week 12 in adverse events.

    Time frame: 12 weeks

  14. Change in anxiety symptoms

    Change from baseline to week 12 from baseline to week 12 in Hamilton Anxiety Rating Scale (HAM-A) total score. Scores range from 0 - 56; a higher score indicates a higher level of anxiety.

    Time frame: 12 weeks

  15. Change in stress symptoms

    Change from baseline to week 12 in Depression Anxiety Stress Scales (DASS-42) Stress Subscale score. Scores range from 0-42; a higher score indicates a higher level of stress.

    Time frame: 12 weeks

  16. Change in cognitive performance

    Change from baseline to week 12 in Matrics Consensus Cognitive Battery (MCCB) Total Score. Scores range from 0.00% - 100.00%; a higher score indicates higher cognition.

    Time frame: 12 weeks

  17. Change in Global Functioning Scale (GFS) - Social and Role total score

    Change from baseline to week 12 in Global Functioning Scale (GFS) - Social and Role total score. Scores range from 6-60; a lower score indicates worse social and role functioning.

    Time frame: 12 weeks

  18. Change in cell-free mitochondrial DNA (cf-mtDNA)

    Change from baseline to week 12 in blood and saliva cf-mtDNA levels.

    Time frame: 12 weeks

  19. Change in growth differentiation factor 15 (GDF15)

    Change from baseline to week 12 in blood and saliva GDF15 levels.

    Time frame: 12 weeks

  20. Change in blood NAD/NADH+ ratio

    Change from baseline to week 12 in blood NAD/NADH+ ratio.

    Time frame: 12 weeks

  21. Change in blood GSH/GSSH ratio

    Change from baseline to week 12 in blood GSH/GSSH ratio.

    Time frame: 12 weeks

Other outcomes

  1. Change in World Health Organization Disability Assessment Schedule (WHODAS) score

    Change from baseline to week 12 in World Health Organization Disability Assessment Schedule (WHODAS) scale. Scores range from 0-144. A higher score indicates greater dysfunction and disability in major life domains.

    Time frame: 12 weeks

  2. Change in World Health Organization Quality of Life (WHOQOL) score

    Change from baseline to week 12 in World Health Organization Quality of Life (WHOQOL) scale. Scores range from 1-130. A lower score indicates lower perceived quality of life.

    Time frame: 12 weeks

  3. Change in Extrapyramidal Symptom Rating Scale (ESRS) total score

    Change from baseline to week 12 in Extrapyramidal Symptom Rating Scale (ESRS) total score. Scores range from 0-102; a higher score indicates more severe symptoms.

    Time frame: 12 weeks

  4. Change in Pittsburgh Sleep Quality Index (PSQI) total score

    Change from baseline to week 12 in Pittsburgh Sleep Quality Index (PSQI) total score. Scores range from 0-21; a higher score indicates worse sleep quality.

    Time frame: 12 weeks

  5. Change in resting-state fMRI

    Change within network positive correlations and between network negative correlations from baseline to week 12.

    Time frame: 12 weeks

  6. Change in gray matter volume

    Change in the gray matter volumes (cubic millimeters) of the frontal, parietal and temporal lobes as defined by Freesurfer's Desikan-Killiany Brain Atlas from baseline to week 12.

    Time frame: 12 weeks

  7. Change in cortical surface area

    Change in the cortical surface area (millimeters squared) of the frontal, parietal and temporal lobes as defined by Freesurfer's Desikan-Killiany Brain Atlas from baseline to week 12.

    Time frame: 12 weeks

  8. Change in white matter fractional anisotropy (FA)

    Change in fractional anisotropy (FA), a scalar measure of diffusivity, of water in the brain assessed by DTI at 3T from baseline to week 12. FA values range from 0 (isotropic, meaning diffusion is equally restricted in 3D space) to 1 (anisotrophic, meaning that diffusion is completely restricted to a single direction).

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2027, 42 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 42 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2024
First posted
Jan 24, 2024
StartActual
Mar 12, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06221852
Lead sponsor
Mclean Hospital
Collaborators
Baszucki Family Foundation
Responsible party
Virginie-Anne Chouinard, MD (Psychiatrist, Mclean Hospital) — Principal investigator
First posted
Jan 24, 2024
Start date
Mar 12, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Kaitlin Shannon, B.A.
Contact
kshannon6@mgb.org
617-855-2410
Virginie-Anne Chouinard, MD
Contact
vchouinard@mclean.harvard.edu
Virginie-Anne Chouinard, MD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion